We urge you to utilize Edwards Lifesciences fundamental analysis to see if markets are presently mispricing the company. In plain English you can exercise it to find out if Edwards Lifesciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-five available fundamental indicators for Edwards Lifesciences Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 49.56 times, we urge you verify Edwards Lifesciences Corporation prevailing market performance to make sure the company can sustain itself down the road.Use Edwards Lifesciences to protect against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Edwards Lifesciences to be traded at $132.91 in 30 days
Edwards Lifesciences Valuation Over Time
Edwards Lifesciences Company SummaryEdwards Lifesciences competes with Express Scripts, AmerisourceBergen, Baxter International, and BECTON DICKINSON. Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Appliances Equipment classification in USA and traded on New York Stock Exchange exchange.
Edwards Lifesciences Return On Asset vs Operating Margin
Edwards Lifesciences Corporation is rated # 2 in return on asset category among related companies. It is rated # 2 in operating margin category among related companies reporting about 2.38 of Operating Margin per Return On Asset.